VLX103, a first-in-class
hepatoselective LPS neutralizer

for the treatment
of liver diseases.

Learn More >

OE_SiteWeb_BulleImage_Hommebleu

Verlyx Pharma to present data
entitled "VLX103 prevents the
development of alcoholic
liver disease in mice"
at
The Liver Meeting® 2015:
November 13-17.

AASLD 2015